Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 8 art units • 16 examiners • 0 of 19 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
R.P. Scherer Technologies LLC has 20 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 8 distinct art units and involve 17 distinct examiners. The distribution shows that most examiners are handling a single pending action for the company. This variety of examiners across 8 art units suggests that the company's biotechnology filings cover several specialized sub-disciplines within the field.
The busiest examiner for this portfolio is DAVID BROWE, who is responsible for 2 pending actions. This accounts for 2 of the 20 total pending office actions. With 17 distinct examiners managing the workload, the company maintains a diverse range of examiner contacts. For patent practitioners, this indicates that prosecution strategies must be tailored to individual examiners rather than relying on a centralized relationship with a single patent office official. The presence of 8 distinct art units further emphasizes the need for technical breadth in handling this portfolio.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 5 (26%) |
| §112 only | 3 (16%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 7 (37%) |
| Multi-statute (no §101) | 2 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWE, DAVID | 2 | 26.4% | +27.3% |
| SKOKO III, JOHN JOSEPH | 2 | 53.1% | +58.2% |
| KASSA, TIGABU | 2 | 36.7% | +27.9% |
| VU, JAKE MINH | 1 | 41.1% | +27.2% |
| JOHNSON, DANIELLE D | 1 | 45.0% | +12.9% |
| KANAAN, LIZA TONY | 1 | 23.4% | +31.5% |
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
| CRAIGO, WILLIAM A | 1 | 49.2% | +38.2% |
| ISNOR, ALEXANDRA NICOLE | 1 | 28.6% | +23.7% |
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724812 | PHARMACEUTICAL TRIALS SYSTEMS AND METHODS | KANAAN, LIZA TONY | 43d overdue |
| 18940147 | FAST DISSOLVING SOFTGEL CAPSULES | BROWE, DAVID | 6d |
| 18516302 | Softgel Capsule and Method of Marking a Softgel Capsule | ISNOR, ALEXANDRA NICOLE | 35d |
| 19300899 | SOFTGEL CAPSULES AND A METHOD FOR PREPARING THE SOFTGEL CAPSULES | BROWE, DAVID | — |
| 17594677 | MINI SOFTGEL NAPROXEN COMPOSITION | BABSON, NICOLE PLOURDE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724812 | PHARMACEUTICAL TRIALS SYSTEMS AND METHODS | KANAAN, LIZA TONY | 43d overdue |
| 18516295 | Softgel Capsule and Method of Marking a Softgel Capsule | KASSA, TIGABU | 1d overdue |
| 18940147 | FAST DISSOLVING SOFTGEL CAPSULES | BROWE, DAVID | 6d |
| 18516302 | Softgel Capsule and Method of Marking a Softgel Capsule | ISNOR, ALEXANDRA NICOLE | 35d |
| 19300899 | SOFTGEL CAPSULES AND A METHOD FOR PREPARING THE SOFTGEL CAPSULES | BROWE, DAVID | — |
| 18908883 | METHOD TO RELIEVE STRESS IN CAPSULE SHELLS TO REDUCE PROPENSITY TO BREAK | VU, JAKE MINH | — |
| 18802287 | ENTERIC SOFTGEL CAPSULES | JOHNSON, DANIELLE D | — |
| 18579065 | Methods of Using Antibody-Drug-Conjugates | SKOKO III, JOHN JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1619 | 5 |
| 1617 | 2 |
| 1611 | 2 |
| 1615 | 2 |
| 3683 | 1 |
| 1624 | 1 |
| 1612 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19300899 | SOFTGEL CAPSULES AND A METHOD FOR PREPARING THE SOFTGEL CAPSULES | BROWE, DAVID | 1617 | §103§112 | Non-Final OA | — | Pending | Aug 15, 2025 |
| 18940147 | FAST DISSOLVING SOFTGEL CAPSULES | BROWE, DAVID | 1617 | §103 | Non-Final OA | 6d | Pending | Nov 07, 2024 |
| 18908883 | METHOD TO RELIEVE STRESS IN CAPSULE SHELLS TO REDUCE PROPENSITY TO BREAK | VU, JAKE MINH | — | DP | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18802287 | ENTERIC SOFTGEL CAPSULES | JOHNSON, DANIELLE D | 1611 | §112Other | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18724812 | PHARMACEUTICAL TRIALS SYSTEMS AND METHODS | KANAAN, LIZA TONY | 3683 | §101§103 | Final Rejection | 43d overdue | Pending | Jun 27, 2024 |
| 18579065 | Methods of Using Antibody-Drug-Conjugates | SKOKO III, JOHN JOSEPH | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18578690 | Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) Antibody-Maytansine Conjugates and Methods of Use Thereof | MELCHIOR, JAMES RYLAND | — | §112Other | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18575474 | SOFTGEL CAPSULE | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | — | Pending | Dec 29, 2023 |
| 18516302 | Softgel Capsule and Method of Marking a Softgel Capsule | ISNOR, ALEXANDRA NICOLE | 1611 | §103DP | Non-Final OA | 35d | Pending | Nov 21, 2023 |
| 18516295 | Softgel Capsule and Method of Marking a Softgel Capsule | KASSA, TIGABU | 1619 | §103 | Final Rejection | 1d overdue | Pending | Nov 21, 2023 |
| 18276432 | Branched Linkers for Antibody-Drug Conjugates and Methods of Use Thereof | MOORE, SUSANNA | 1624 | §112DP | Non-Final OA | — | Pending | Aug 08, 2023 |
| 18208635 | ENTERIC BISACODYL SOFTGEL CAPSULE | KASSA, TIGABU | 1619 | §103 | Final Rejection | — | Pending | Jun 12, 2023 |
| 18036207 | DELAYED RELEASE SOFTGEL CAPSULES | MITCHELL, EDWIN COLEMAN | 1619 | §103DP | Non-Final OA | 43d | Pending | May 10, 2023 |
| 18300905 | SYSTEMS AND METHODS FOR PROVIDING OPTIMAL PROCESS PARAMETERS FOR FLUID BED GRANULATION SYSTEMS | CALLE, ANGEL JAVIER | — | §103 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 17910999 | SOFTGEL CAPSULES | WERTZ, ASHLEE ELIZABETH | 1612 | §112 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17582616 | MINI SOFTGEL NAPROXEN COMPOSITION | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Final Rejection | 31d overdue | Pending | Jan 24, 2022 |
| 17596059 | DELAYED RELEASE SOFTGEL CAPSULES | PROSSER, ALISSA J | 1619 | §103§112DP | Final Rejection | 27d | Pending | Dec 02, 2021 |
| 17594677 | MINI SOFTGEL NAPROXEN COMPOSITION | BABSON, NICOLE PLOURDE | 1619 | §103§112 | Non-Final OA | — | Pending | Oct 26, 2021 |
| 17423796 | Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates | SKOKO III, JOHN JOSEPH | 1643 | §103DP | Non-Final OA | — | Pending | Jul 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial